Results 211 to 220 of about 2,034,935 (392)

Single Cell Analysis Reveals Dynamic Changes of Distinct Cell Populations in Human Nickel Allergy

open access: yesAllergy, EarlyView.
We investigated cell types mediating the early and late inflammatory responses in human Ni2+‐allergy by scRNA‐Seq. Early responsiveness was mainly mediated by TLR4+TAGLN− endothelial cells indirectly activating TLR4−KRT16+ keratinocytes, and CCR7+DCN+ DCs. Late responsiveness was crucially driven by infiltration of KLF2+ central memory T cells and TLR4+
Marc Schmidt   +7 more
wiley   +1 more source

Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine

open access: yesAmerican journal of hematology/oncology, 2021
O. H. Tarawneh, Husam S Tarawneh
semanticscholar   +1 more source

PO-0165 Predictors Of Chronic Primary Immune Thrombocytopenia [PDF]

open access: bronze, 2014
L. Sfaihi   +6 more
openalex   +1 more source

Differential Impact of Polymyxin B Hemadsorption on Long‐Term Mortality in Septic Shock: A Retrospective Analysis of Intra‐Abdominal Versus Extra‐Abdominal Infections

open access: yesArtificial Organs, EarlyView.
In this single‐center retrospective cohort study, the use of PMX‐HA was significantly associated with a reduced risk of 1‐year mortality in patients with septic shock due to intra‐abdominal infection. In contrast, no significant association was observed between PMX‐HA use and 1‐year mortality risk in patients with septic shock caused by extra‐abdominal
Tomoki Tanaka   +9 more
wiley   +1 more source

Iron Deficiency in Immune Thrombocytopenia: Are We Doing Enough? [PDF]

open access: bronze
Analy Mora   +7 more
openalex   +1 more source

Non‐Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In a multi‐centre study of obeticholic acid in primary biliary cholangitis, 45% discontinued the drug over 4 years, with 11% moving to combination therapy (fibrates). Of those continuing, response rates increased from 37% (1 year) to 55% (4 years). Non‐response at 12 months and cirrhosis were independent predictors of liver‐related events.
Nadir Abbas   +18 more
wiley   +1 more source

Efficacy of ciclosporin monotherapy in non‐severe aplastic anaemia not requiring transfusions: Results from a multicentre phase II study

open access: yesBritish Journal of Haematology, EarlyView.
Summary The efficacy of ciclosporin (CsA) to treat transfusion‐independent non‐severe aplastic anaemia (TI‐NSAA) has not yet been systematically evaluated. We conducted a prospective trial in patients with TI‐NSAA treated with CsA monotherapy. CsA (3.5 mg/kg/day) was administered to patients with TI‐NSAA aged ≥16.
Ken Ishiyama   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy